HOME >> BIOLOGY >> NEWS
Media advisory: CDC flu update teleconference

Please note 1 pm start time and new telephone number for this telebriefing

WHO: Dr. Keiji Fukuda, CDC influenza expert

WHAT: Dr. Fukuda will provide an update on influenza and vaccine issues.

Brief remarks followed by media Q/A.

WHEN: Friday, December 21, 2001; 1 2 PM EST

WHERE: At your desk, by toll-free conference line: Dial (800) 288-8968 Teleconference name: CDC

WHY: Get the most recent information about influenza and vaccine issues.

A full transcript of this teleconference will be available by 4 p.m. EST, following the teleconference on the CDC website at www.cdc.gov/od/oc/media

#
'"/>

Contact: CDC, Media Relations
404-639-3286
Centers for Disease Control and Prevention
20-Dec-2001


Page: 1

Related biology news :

1. Media advisory: Sea of Cortez expedition to launch March 26
2. Media invited to attend International Society For Heart & Lung Transplantation meeting April 21-24
3. AMA Alzheimers Media Briefing
4. Media alert: Mideast briefing
5. Media Advisory-GSA 2003 Annual Meeting
6. Media advisory - wildland fire impacts on watersheds
7. Media seminar on cardiovascular medicine
8. Media Advisory
9. UCLA offers CASE Media fellowships on genetics, society and the individual
10. Media alert: press briefings and special sessions at the GSAs Annual Meeting
11. When Media, Science and Public Policy Collide: The Case of Food and Biotechnology

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Media advisory CDC flu update teleconference

(Date:5/23/2013)... mechanism by which estrogen suppresses lipid synthesis in the ... approach toward treating certain liver diseases. , With ... are changing long-held views in the field. Study results ... Science Signaling . , "The dogma in the ... only receptors located in the nucleus respond to steroid ...
(Date:5/23/2013)... new report from the Institute of Medicine says schools ... least 60 minutes of vigorous or moderate intensity activity ... of American youth meet current evidence-based guidelines of at ... activity daily, according to the report, which was released ... nearly half of their waking hours, the committee recommends ...
(Date:5/23/2013)... in Neuron , the team reveal the interplay ... work funded by the Wellcome Trust and BBSRC. ... stimuli we improve our perceptual abilities. While these changes ... can also affect the fidelity of that response. ... Neuroscience explains: "When you communicate with others, you can ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide students with daily physical activity, IOM recommends 2
(Date:5/23/2013)... San Francisco, CA (PRWEB) May 23, 2013 ... do-it-yourselfers who encourage all types of inventions. They focus ... we’re now noticing this community gravitate toward bringing their ... community, the DIY Biology Movement, works on making projects ... sequencing the DNA of plants to make them glow ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
(Date:5/23/2013)... Toronto, Canada (PRWEB) May 23, 2013 ... subjects, it is critical to adhere to principles ... protection (HSP). , Esteemed speaker Dr. Jeremy Lim, ... the audience: , ,     Understand the ... Clinical Practice (GCP) and additional regulations for the ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
Cached News: